Technical Analysis for XOMA - XOMA Corporation

Grade Last Price % Change Price Change
C 25.18 -4.33% -1.14
XOMA closed down 4.33 percent on Monday, March 18, 2024, on 74 percent of normal volume. The bulls were able to push the stock to a new 52-week high.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
MACD Bullish Signal Line Cross Bullish -4.33%
New 52 Week Closing High Bullish -4.33%
Pocket Pivot Bullish Swing Setup -4.33%
Volume Surge Other -4.33%
Stochastic Reached Overbought Strength -4.33%
Outside Day Range Expansion -4.33%
Overbought Stochastic Strength -4.33%

   Recent Intraday Alerts

Alert Time
Down 3% about 8 hours ago
Fell Below 10 DMA about 8 hours ago
Down 1 ATR about 8 hours ago
Down 2 % about 9 hours ago
Down 1% about 10 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

XOMA Corporation Description

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçet's uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The company's proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Immune System Infectious Diseases Diabetes Antibodies Monoclonal Antibodies Antibody Prostate Cancer Cardiovascular Disease Hypertension Non Small Cell Lung Cancer Small Cell Lung Cancer Allergy Multiple Myeloma Vascular Disease Osteoarthritis Acne Metabolic Disorders Platform Technologies Uveitis Inflammatory Human Monoclonal Antibodies Botulism Antibody Product Non Infectious Uveitis

Is XOMA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 26.8299
52 Week Low 13.48
Average Volume 22,048
200-Day Moving Average 17.89
50-Day Moving Average 22.21
20-Day Moving Average 24.80
10-Day Moving Average 25.42
Average True Range 1.27
RSI (14) 57.08
ADX 41.27
+DI 24.74
-DI 9.77
Chandelier Exit (Long, 3 ATRs) 23.02
Chandelier Exit (Short, 3 ATRs) 24.32
Upper Bollinger Bands 26.72
Lower Bollinger Band 22.88
Percent B (%b) 0.6
BandWidth 15.48
MACD Line 1.12
MACD Signal Line 1.19
MACD Histogram -0.07
Fundamentals Value
Market Cap 289.26 Million
Num Shares 11.5 Million
EPS -2.81
Price-to-Earnings (P/E) Ratio -8.96
Price-to-Sales 53.15
Price-to-Book 2.26
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.88
Resistance 3 (R3) 28.13 27.48 27.43
Resistance 2 (R2) 27.48 26.79 27.35 27.28
Resistance 1 (R1) 26.33 26.37 26.00 26.08 27.13
Pivot Point 25.68 25.68 25.52 25.55 25.68
Support 1 (S1) 24.53 24.99 24.21 24.28 23.23
Support 2 (S2) 23.88 24.57 23.76 23.08
Support 3 (S3) 22.73 23.88 22.93
Support 4 (S4) 22.48